Cargando…

Long‐term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review

Two phase 3 trials reported a prolonged survival in the third‐line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brunetti, Oronzo, Calabrese, Angela, Palermo, Loredana, Solimando, Antonio Giovanni, Argentiero, Antonella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935656/ https://www.ncbi.nlm.nih.gov/pubmed/31893063 http://dx.doi.org/10.1002/ccr3.2496

Ejemplares similares

Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review
por: Argentiero, Antonella, et al.
Publicado: (2019)

A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report
por: De Summa, Simona, et al.
Publicado: (2021)

Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option
por: Argentiero, Antonella, et al.
Publicado: (2020)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Immune system and bone microenvironment: rationale for targeted cancer therapies
por: Gnoni, Antonio, et al.
Publicado: (2020)

Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview
por: Argentiero, Antonella, et al.
Publicado: (2019)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
por: Longo, Vito, et al.
Publicado: (2019)

Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
por: Gnoni, Antonio, et al.
Publicado: (2019)

Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
por: Argentiero, Antonella, et al.
Publicado: (2020)

Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
por: Solimando, Antonio Giovanni, et al.
Publicado: (2021)

Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy
por: Fasano, Rossella, et al.
Publicado: (2021)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study
por: Argentiero, Antonella, et al.
Publicado: (2019)

A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery
por: Shadbad, Mahdi Abdoli, et al.
Publicado: (2021)

Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Angiogenesis in adenosquamous cancer of pancreas
por: Silvestris, Nicola, et al.
Publicado: (2017)

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
por: Sastre, J., et al.
Publicado: (2014)

Photodynamic Therapy with Zinc Phthalocyanine Inhibits the Stemness and Development of Colorectal Cancer: Time to Overcome the Challenging Barriers?
por: Gholizadeh, Mahsa, et al.
Publicado: (2021)

Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2022)

Corrigendum: Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2023)

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature
por: Zhang, Yong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
por: Makaremi, Shima, et al.
Publicado: (2021)

Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era
por: Burgaletto, Chiara, et al.
Publicado: (2021)

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study
por: Unseld, Matthias, et al.
Publicado: (2020)

CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
por: Porcelli, Letizia, et al.
Publicado: (2019)

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
por: Strumberg, D, et al.
Publicado: (2012)

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
por: Hendlisz, Alain, et al.
Publicado: (2015)

Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection
por: Paradiso, Angelo Virgilio, et al.
Publicado: (2020)

Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis
por: Derakhshani, Afshin, et al.
Publicado: (2022)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
por: Martinelli, Erika, et al.
Publicado: (2017)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
por: Roman, Danielle, et al.
Publicado: (2013)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
por: Yan, Yiyi, et al.
Publicado: (2015)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
por: Wong, Andrea Li Ann, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jds64p4gdnajumhq4u55a3k3t8